scispace - formally typeset
Search or ask a question

Showing papers in "Vaccine in 1995"


Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: Progress has been made on development, isolation and chemical synthesis of alternative adjuvants such as derivatives of muramyl dipeptide, monophosphoryl lipid A, liposomes, QS21, MF-59 and immunostimulating complexes (ISCOMS).

583 citations


Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: Several countries of 'low' endemicity are also recommending hepatitis B immunization of all newborns or adolescents, realising that the strategy of 'high-risk group' immunization has failed to control HBV infection even in areas of low endemicity.

422 citations


Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: It is suggested that LGG has an immunostimulating effect on oral rotavirus vaccination and the clinical significance of LGG-enhanced immune responses to oral vaccines should be further evaluated.

369 citations


Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: Data are presented demonstrating that a simple, hand-held version of the Accell DNA delivery system, employing compressed helium as the particle motive force, achieves immune responses comparable to the traditional electric discharge device.

320 citations


Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: A meningococcal group B (15:P1.3) outer membrane protein vaccine was tested for efficacy in a randomized, double-blind controlled study in Iquique, Chile as discussed by the authors.

259 citations


Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: The kinetics of the interferon-gamma response of peripheral blood lymphocytes cultured in vitro with bovine PPD showed that BCG vaccination induced a rapid rise in the response followed by a sharp decline, while infection with virulent M. bovis resulted in an increase in the interFERon-Gamma response by four weeks after challenge and this response remained high through the study.

255 citations


Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: Vaccination of mice with M2 shortened the duration of virus shedding and protected mice from a lethal infection with A/Ann Arbor/6/60 virus but not B/ Ann Arbor/1/55 virus, suggesting that the protection was mediated by an M2-specific mechanism.

217 citations


Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: Perinatal infection with variants of hepatitis B virus occurs despite combined immunoprophylaxis with hepatitis B immunoglobulin and currently licensed plasma-derived and recombinant yeast hepatitis B vaccines.

206 citations


Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: QS-21 derivatives modified at an aldehyde on the triterpene did not show adjuvant activity for antibody stimulation or for induction of cytotoxic T-lymphocytes, suggesting that this functional group may be involved in the adjUvant mechanism.

191 citations


Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: Two computer-based algorithms for T cell epitope prediction, OptiMer and EpiMer, are designed, which incorporate current knowledge of MHC-binding motifs, and it is demonstrated that these two algorithms may provide sensitive and efficient means for the prediction of promiscuous Tcell epitopes that may be critical to the development of vaccines against these and other pathogens.

189 citations


Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: The relative efficacy of a live attenuated vaccine strain of Y. pestis (EV76) was compared with that of the formaldehyde-killed vaccine (Plague vaccine, USP).

Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: In the cottontail rabbit papillomavirus (CRPV) system, it is demonstrated that recombinant CRPV virus-like particles (VLPs) consisting of the capsid proteins L1 or L1+L2 can be produced in the yeast Saccharomyces cerevisiae, suggesting that recombinate yeast-derived VLPs could be the basis for a candidate HPV vaccine.

Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: The proliferative and antibody responses induced by a single injection of three TT-MS mixtures with different particle sizes and degradation rates were similar to those obtained with three injections of TT-alum.

Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: PLG microparticles are a safe and effective means of delivering antigen to the appropriate processing site for the generation of class I-restricted CTL, and are also capable of inducing Th1 cells.

Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: These studies show that different routes of immunization can be effective for the induction of specific antibodies, and support the concept of the common mucosal immune system in humans by demonstrating that the oral or intranasal administration of antigen-induced specific antibodies of IgA isotype in external secretions is preceded by the transient appearance in peripheral blood of specific antibody-producing cells.

Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: It is shown that i.n.p. immunization of female mice with this same vector, AdgB8, provides secretory and serum-derived humoral immune responses in the genital tract and demonstrates the highest level of serum anti-HSVgB IgA.

Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: Starting with Neisseria meningitidis strain H44/76, a set of strains was constructed for use in production of a multivalent outer membrane vesicle vaccine to remove unwanted outer membrane components and at the same time to improve the range of protection.

Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: The 200-300 nm diameter emulsion formulation MF59 containing only the low toxicity components squalene, Tween 80 and Span 85 has been shown to enhance titers from 5 to 250 times that achievable with vaccine alone.

Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: The main properties of adenoviruses which render them attractive for vaccine development, as well as the results of the immunization studies performed to date are reviewed.

Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: A modified tobacco mosaic virus was used to direct the synthesis of TMV coat protein hybrids containing a 13 amino acid sequence of the murine zona pellucida ZP3 protein, which was found to be robust and accumulate to high concentrations in inoculated plants.

Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: It was demonstrated that a Quillaja component, designated QH-C, either as a "free" component or in an ISCOM matrix, has a strong adjuvant activity, but little or no toxicity in the doses tested.

Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: Analysis of viral-specific DNA accumulation indicated that the block in the replication cycle in the human cell lines analyzed occurred prior to DNA replication, indicating the safety and immunogenicity of the ALVAC vaccine vector.

Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: The PA+MPL in SLT vaccine, which was lyophilized and then reconstituted before use, demonstrated strong protective immunogenicity, even after storage for 2 years at 4 degrees C, and the MPL component was required for maximum efficacy of the vaccine.

Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: In this paper, the effect of ionic strength and ethylene glycol on the adsorption of bovine serum albumin (BSA) or lysozyme by a commercial aluminium hydroxide or aluminium phosphate adjuvant was studied at pH 7.4 and 25°C.

Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: The result indicates that a successful maternal vaccine against coccidiosis requires, in addition to good recognition of protective antigens, the exclusion of irrelevant antigen from the vaccine preparation.

Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: Additional attenuating mutations, such as small-plaque (sp) or ts mutations, are introduced into RSV cpts-530 by chemical mutagenesis with 5-fluorouracil with the intent of obtaining derivatives of RSV that are more attenuated in mice or chimpanzees and that were more stable genetically following replication in vivo.

Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: Using different forms of the envelope glycoprotein E from tick-borne encephalitis virus, Rosettes and RSPs were excellent immunogens and exhibited similar efficacies as inactivated virus in terms of antibody induction and protection against challenge, whereas all of the soluble forms were much less immunogenic.

Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: An experimental rabies vaccine was prepared from the BHK-21 cell line adapted to culture in suspension using bioreactors and had satisfactory protective activity when tested in mice.

Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: It is concluded that liposomes, administered i.n., provide a promising adjuvant system for stimulation of antibody responses in general, and mucosal sIgA responses in particular.

Journal ArticleDOI
01 Jan 1995-Vaccine
TL;DR: Results clearly showed that the recombinant vaccine Gavac is able to control tick numbers in successive generations in the field, as in the Cuban study.